AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04341103

Acronym

Al-COVE

Enrollment

500

Registered

2020-04-10

Start date

2020-04-01

Completion date

2021-03-01

Last updated

2020-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, Solid Organ Transplant Rejection

Brief summary

The utilization of AlloSure to help guide immunosuppression management in solid organ transplant recipients diagnosed with COVID-19

Detailed description

An observational case series of patients with solid organ transplants who have been admitted with suspected COVID-19 utilizing AlloSure dd-cf DNA to help guide immunosuppression management balancing the treatment of sepsis and avoiding allograft rejection.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Liver, Heart, Lung or Kidney organ transplant recipient with a suspected or confirmed diagnosis of COVID-19

Design outcomes

Primary

Measure	Time frame	Description
Assessing the utility of AlloSure dd-cfDNA to guide clinical immune-optimization for transplant patients with COVID-19	6 months	AlloSure dd-cfDNA blood draw values

Contacts

Primary ContactAlana Burns

aburns@caredx.com415.287.2420

Outcome results